Cheng-Kon Shih

1.3k citations

16 papers · 1.1k indexed · 1 hit paper · h-index 13

Co-authors: Joseph C. Wu Karl D. Hargrave Vincent J. Merluzzi Mark T. Skoog Julian Adams Susan E. Hattox Mark E. Labadia Robert J. Eckner
Topics: HIV Research and Treatment (7 papers)HIV/AIDS drug development and treatment (7 papers)Click Chemistry and Applications (2 papers)
Cited by: Virology Infectious Diseases Organic Chemistry
Journals: Science Nucleic Acids Research Nature Medicine
Partner nations: United States Germany China

In The Last Decade

Cheng-Kon Shih

16 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor

1990 653 citations Vincent J. Merluzzi, Karl D. Hargrave et al. Science profile →

Peers

Countries citing papers authored by Cheng-Kon Shih

Since Specialization

Citations

This map shows the geographic impact of Cheng-Kon Shih's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheng-Kon Shih with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheng-Kon Shih more than expected).

Fields of papers citing papers by Cheng-Kon Shih

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheng-Kon Shih. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheng-Kon Shih. The network helps show where Cheng-Kon Shih may publish in the future.

Co-authorship network of co-authors of Cheng-Kon Shih

This figure shows the co-authorship network connecting the top 25 collaborators of Cheng-Kon Shih. A scholar is included among the top collaborators of Cheng-Kon Shih based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheng-Kon Shih. Cheng-Kon Shih is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Development of an HPLC–MS/MS Method to Determine Janagliflozin in Human Plasma and Urine: Application in Clinical Study 2018 ·Bioanalysis ·Ling Song,Yang Liu,Xueting Yao,Hongzhong Liu,Qing Chen,(unknown),Huimin Zhou,Cheng-Kon Shih,Ji Jiang,Xijing Chen,Pei Hu,Dongyang Liu	7
2	Developing a novel dual PI3K–mTOR inhibitor from the prodrug of a metabolite 2017 ·OncoTargets and Therapy ·Yan Zhou,(unknown),(unknown),Jin Wang,(unknown),Xinyu Li,(unknown),Jiakui Li,Cheng-Kon Shih,You Song	1
3	Discovery of Imigliptin, a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes 2014 ·ACS Medicinal Chemistry Letters ·(unknown),Ge Hu,Michael Song,(unknown),Huimin Zhou,Qi Qu,(unknown),(unknown),(unknown),(unknown),(unknown),Dapeng Zhou,Peng Peng,Cheng-Kon Shih,Jun Xu,Frank Wu	32
4	Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account 2010 ·Bioorganic & Medicinal Chemistry Letters ·Frank Wu,Frank Büttner,(unknown),Eugene R. Hickey,Scott Jakes,Paul V. Kaplita,Mohammed A. Kashem,Steven Kerr,Stanley Kugler,(unknown),Anthony S. Prokopowicz,Cheng-Kon Shih,Roger J. Snow,Erick R. R. Young,Charles L. Cywin	15
5	Hit to Lead Account of the Discovery of Bisbenzamide and Related Ureidobenzamide Inhibitors of Rho Kinase 2009 ·Journal of Medicinal Chemistry ·Tina M. Morwick,Frank Büttner,Charles L. Cywin,Georg Dahmann,Eugene R. Hickey,Scott Jakes,Paul V. Kaplita,Mohammed A. Kashem,Steven Kerr,Stanley Kugler,Mao Wang,Daniel R. Marshall,(unknown),Cheng-Kon Shih,Frank Wu,Erick R. R. Young	8
6	Identification of dissociated non-steroidal glucocorticoid receptor agonists 2007 ·Bioorganic & Medicinal Chemistry Letters ·Daniel Kuzmich,(unknown),John Proudfoot,(unknown),Renée Zindell,Laura Beck,Richard M. Nelson,Cheng-Kon Shih,Alison Kukulka,(unknown),(unknown),(unknown),Mario Cardozo,Gerald Nabozny,David Thomson	26
7	Trifluoromethyl group as a pharmacophore: Effect of replacing a CF3 group on binding and agonist activity of a glucocorticoid receptor ligand 2005 ·Bioorganic & Medicinal Chemistry Letters ·Raj Betageri,Yan Zhang,Renée Zindell,Daniel Kuzmich,(unknown),Jörg Bentzien,Mario Cardozo,(unknown),(unknown),Richard M. Nelson,(unknown),Daw-Tsun Shih,Cheng-Kon Shih,Ljiljana Žuvela-Jelaska,Gerald Nabozny,David Thomson	89
8	Novel Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. 8. 8-Aryloxymethyl- and 8-Arylthiomethyldipyridodiazepinones 1998 ·Journal of Medicinal Chemistry ·Charles L. Cywin,Janice M. Klunder,(unknown),(unknown),Eva David,Peter M. Grob,(unknown),Daniel Pauletti,Kevin Barringer,Cheng-Kon Shih,Christopher L. Sorge,David A. Erickson,David Joseph,Susan E. Hattox	24
9	Novel Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. 7. 8-Arylethyldipyridodiazepinones as Potent Broad-Spectrum Inhibitors of Wild-Type and Mutant Enzymes 1998 ·Journal of Medicinal Chemistry ·Janice M. Klunder,(unknown),Charles L. Cywin,Eva David,(unknown),(unknown),Kevin Barringer,Daniel Pauletti,Cheng-Kon Shih,David A. Erickson,Christopher L. Sorge,David Joseph,Susan E. Hattox,Julian Adams,Peter M. Grob	27
10	Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase 1997 ·Nature Medicine ·Peter M. Grob,Yunzhen Cao,Elizabeth Muchmore,David D. Ho,(unknown),Joseph Pav,Cheng-Kon Shih,Julian Adams	28
11	Novel Non-Nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase. 6. 2-Indol-3-yl- and 2-Azaindol-3-yl- dipyridodiazepinones 1997 ·Journal of Medicinal Chemistry ·Terence A. Kelly,Daniel W. McNeil,Janice Rose,Eva David,Cheng-Kon Shih,Peter M. Grob	43
12	Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase: Nevirapine as a Prototype Drug 1992 ·AIDS Research and Human Retroviruses ·Peter M. Grob,Joseph C. Wu,K.A. Cohen,Richard H. Ingraham,Cheng-Kon Shih,Karl D. Hargrave,(unknown),Vincent J. Merluzzi	73
13	Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template 1991 ·Nucleic Acids Research ·Elizabeth B. Kopp,(unknown),(unknown),Cheng-Kon Shih,Peter M. Grob,Mark T. Skoog	47
14	Expression of a Proteolipid Gene from a High-Copy-Number Plasmid Confers Trifluoperazine Resistance to Saccharomyces cerevisiae 1990 ·Molecular and Cellular Biology ·Cheng-Kon Shih,Jeffrey W. Kwong,(unknown),Norma Neff	15
15	Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitorbreakdown → 1990 ·Science ·Vincent J. Merluzzi,Karl D. Hargrave,Mark E. Labadia,Karl Grozinger,Mark T. Skoog,Joseph C. Wu,Cheng-Kon Shih,(unknown),Susan E. Hattox,Julian Adams,Alan S. Rosenthal,Ronald B. Faanes,Robert J. Eckner,Richard A. Koup,John L. Sullivan	653
16	A Dominant Trifluoperazine Resistance Gene from Saccharomyces cerevisiae Has Homology with F ₀ F ₁ ATP Synthase and Confers Calcium-Sensitive Growth 1988 ·Molecular and Cellular Biology ·Cheng-Kon Shih,(unknown),(unknown),(unknown),Norma Neff	16

About Cheng-Kon Shih

Cheng-Kon Shih is a scholar working on Virology, Infectious Diseases and Toxicology, having authored 16 papers that have together received 1.1k indexed citations. Recurring topics across this work include HIV Research and Treatment (7 papers), HIV/AIDS drug development and treatment (7 papers) and Click Chemistry and Applications (2 papers). The work is most often cited by research in Virology (595 citations), Infectious Diseases (681 citations) and Organic Chemistry (348 citations). Cheng-Kon Shih has collaborated with scholars based in United States, Germany and China. Frequent co-authors include Joseph C. Wu, Karl D. Hargrave, Vincent J. Merluzzi, Mark T. Skoog, Julian Adams, Susan E. Hattox, Mark E. Labadia, Robert J. Eckner, John L. Sullivan and Alan S. Rosenthal. Their work appears in journals such as Science, Nucleic Acids Research and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact